Eliem Therapeutics is a biotechnology company delivering therapies that empower patients to live on their own terms. Backed by RA Capital Management, Access Biotechnology, and Intermediate Capital Group, Eliem channels its experience, energy, and passion for improving patients’ quality of life by developing and commercializing potentially “best-in-class” drug candidates to treat neuronal excitability disorders. These conditions—such as chronic pain, depression, epilepsy, and anxiety—cause deep suffering for tens of millions of people each day. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.
Location: United States, Washington, Redmond
Employees: 11-50
Total raised: $140M
Founded date: 2018
Investors 3
Funding Rounds 2
| Date | Series | Amount | Investors |
| 24.05.2021 | Series B | $60M | RA Capital... |
| 25.03.2021 | - | $80M | - |
Mentions in press and media 19
| Date | Title | Description |
| 03.08.2022 | PhIII fail in overall survival measure clouds Ipsen's expansion plans for cancer drug Onivyde | In April, Eliem Therapeutics’ lead candidate, ETX-810, failed a Phase II study for diabetic nerve pain, buckling the greater Seattle-based biotech’s stock by over half. At the time, Eliem CEO and president Bob Azelby called the results “una... |
| 18.01.2022 | Eliem Therapeutics Provides Program Updates and an Overview of Expected Near-Term Milestones | ETX-810 Phase 2a trial in diabetic peripheral neuropathic pain (DPNP) is fully enrolled Investigational New Drug (IND) application planned in Q1 2022 for ETX-155 Phase 2 trials in major depressive disorder (MDD) and perimenopausal depressio... |
| 09.11.2021 | Eliem Therapeutics Reports Third Quarter Financial and Business Highlights - Form 8-K | Eliem Therapeutics Reports Third Quarter Financial and Business Highlights Advanced ETX-155 clinical development program, with the first subject successfully screened in epilepsy proof-of-concept trial and significant progress made toward t... |
| 09.11.2021 | Eliem Therapeutics Reports Third Quarter Financial and Business Highlights | Advanced ETX-155 clinical development program, with the first subject successfully screened in epilepsy proof-of-concept trial and significant progress made toward the initiation of major depressive disorder (MDD) and perimenopausal depress... |
| 13.09.2021 | Eliem Therapeutics : Reports Second Quarter Financial Results | On track to advance two clinical programs through five proof-of-concept trials and progress two preclinical programs over the next 18-24 months Recently completed an IPO for $92 million in gross proceeds that, along with existing cash, prov... |
| 19.07.2021 | Eliem Therapeutics files for IPO as another Seattle-area biotech firm set to go public | Bob Azelby. (Eliem Photo) Eliem Therapeutics, a clinical stage biotech company generating therapies for pain, depression and other nervous-system related conditions, has filed to go public via an IPO. The company’s filing with the U.S. Secu... |
| 24.05.2021 | INTERMEDIATE CAPITAL GROUP PLC Eliem Therapeutics : Announces $60 Million Series B Financing | SEATTLE and CAMBRIDGE, England, May 24, 2021 /PRNewswire/ -- Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in disorders of t... |
| 24.05.2021 | Seattle neurology startup Eliem Therapeutics raises $60M, two months after landing $80M | Bob Azelby. (Eliem Photo) New funding: Eliem Therapeutics raised $60 million to further development of its therapies for pain and depression. The fresh funding comes just two months after Eliem raised a $80 million round. The pipeline: Foun... |
| 24.05.2021 | Eliem Therapeutics Announces $60 Million Series B Financing | |
| 24.05.2021 | Eliem Therapeutics : Announces $60 Million Series B Financing | SEATTLE and CAMBRIDGE, England, May 24, 2021 /PRNewswire/ -- Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in disorders of t... |
Show more